Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer

Added 241 days ago (19.01.2021)
Authors: Tolaney, S. M., Im, Y.-H., Calvo, E., Lu, Y.-S., Hamilton, E., Forero-Torres, A., Bachelot, T., Maur, M., Fasolo, A., Tiedt, R., Nardi, L., Stammberger, U., Abdelhady, A. M., Ruan, S., Lee, S. C.
Read article